RUMORED BUZZ ON ABBV-744 FOR SMALL CELL LUNG CANCER RESEARCH

The present work examined the potential of making use of ARV-825 and ABBV-744 to increase the effectiveness of tamoxifen or fulvestrant in addition palbociclib. ARV-825 was effective in both p53 wild-sort (WT) breast tumor cells and in cells lacking useful p53 both by itself or in combination with tamoxifen, whilst the effectiveness of ABBV-744 was